WO2001085220A1 - Labeled nucleosides and method for their preparation - Google Patents

Labeled nucleosides and method for their preparation Download PDF

Info

Publication number
WO2001085220A1
WO2001085220A1 PCT/EP2001/005366 EP0105366W WO0185220A1 WO 2001085220 A1 WO2001085220 A1 WO 2001085220A1 EP 0105366 W EP0105366 W EP 0105366W WO 0185220 A1 WO0185220 A1 WO 0185220A1
Authority
WO
WIPO (PCT)
Prior art keywords
glucopyranosyl
labeled
ring
previous
glucose
Prior art date
Application number
PCT/EP2001/005366
Other languages
French (fr)
Inventor
Irene Lagoja
Piet Herdewijn
Original Assignee
Rna-Tec N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0011226A external-priority patent/GB0011226D0/en
Priority claimed from EP00870188A external-priority patent/EP1186306A1/en
Application filed by Rna-Tec N.V. filed Critical Rna-Tec N.V.
Priority to AU69003/01A priority Critical patent/AU6900301A/en
Publication of WO2001085220A1 publication Critical patent/WO2001085220A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0491Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers

Definitions

  • the invention relates to a method for the chemical preparation of labeled nucleosides and to the nucleotides obtainable by said method.
  • a bottleneck in NMR research on nucleic acids structures and dynamics is the availability of isotopically labeled materials in larger amounts and at a reasonable cost.
  • 13 C/ 15 N labeled nucleic acids can be obtained by an enzymatic approach, in a chemical way or by a combination of both 1 .
  • 13 C/ 15 N labeled ribomononucleotides can be isolated from bacterial cells grown in isotopically enriched media. These mononucleotides are then converted to their triphosphates using chemical or enzymatic phosphorylation.
  • the labeled nucleoside-5'-triphosphates are then used to prepare RNA from synthetic DNA templates by in vitro transcription with T7 RNA polymerase 2 .
  • the yield of labeled monomers isolated from the cultures as a mixture of four nucleotides is about 4-5%.
  • the conversion of isotopically labeled glucose into nucleotides in a single coupled enzymatic reaction is a much more efficient process 3 . Over a gram of isotopically labeled ribomononucleotides can be obtained from 1 gram of glucose.
  • the labeled deoxynucleotide-5'-triphosphates are incorporated into oligonucleotides using a 3'-5' exonuclease-deficient mutant of Klenow fragment of DNA polymerase I and a DNA template linked to a primer. Region-specific isotopic enrichment was also described using mutated Klenow DNA polymerase and a hairpin template 5 . This method was followed by a more efficient procedure using Taq DNA polymerase 6 . Louis et al.
  • a method for the large scale preparation of uniformly isotope labeled DNA by a) the growth of a suitable plasmid harboring multiple copies of the described oligonucleotide in a medium based on 5 N and 13 C nutrients or b) a polymerase chain reaction with 15 N- and/or 13 C labeled deoxynucleoside triphosphates 7 .
  • the chemical synthesis is much more flexible and allows the preparation of virtually all-possible isotopomeric nucleosides and site specific labeled oligomers 9 . Specific labeling will allow more accurate NMR parameters to be obtained.
  • the chemical approach likewise, opens the possibility to obtain labeled modified nucleosides and oligonucleotides. A more efficient and less costly chemical synthesis would have considerable advantages over the enzymatic approach.
  • the key step in the chemical preparation of fully labeled nucleotides is the synthesis of protected [ 13 C 5 ]-D-ribose, which starts from the readily available [ 13 C 6 ]-D-glucose 10"12 .
  • the overall yield of this conversion is 40%.
  • the [ 13 C 5 ]-1 ,2,3,5-tetra-0-acyl- ⁇ , ⁇ -D-ribofuranose is then converted into the individual protected nucleosides by Vorbruggen condensation 13 , deprotection and tritylation reactions.
  • the disadvantages of the published methods are the multiple steps needed to convert [ 13 C 6 ]- D-glucose into [ 13 C 5 ]- D-ribose.
  • the published methods differ from each other by a) first inversion of configuration by a PDC-NaBH 4 reaction and then oxidative cleavage of the side chain 10 ; b) first shortening of the side chain by a NalO 4 -NaBH 4 reaction followed by inversion of configuration using a nucleophilic substitution reaction 11 ; c) a one pot procedure to oxidative cleave the diol and reduce simultaneously both the 3-keto function and the 6-aldehyde group 12 .
  • the invention relates therefor to a method for the chemical preparation of labeled nucleosides via an oxidative-ring-opening step and a reductive-ring-closure step starting from a labeled D-glucose nucleoside resulting in the corresponding D-ribose-nucleoside by removing the carbon atom 3 on the glucose.
  • the method according to the invention starting from partially or fully labeled D-glucose comprises the steps of:
  • the base is a purine or a pyrimidine
  • the labeled glucose is from the group consisting of [ 13 C 6 ]-D-glucose or a partially labeled D-glucose, and the purine or pyrimidine of step 2 is fully or partially labeled
  • the deprotection of the sugar ring hydroxyl groups is followed by a protection step of the primary OH-group, wherein the primary OH-group is protected as a trityl or silyl ether or by any other protecting group stable to the oxidative-ring- opening and reductive-ring-closure reactions.
  • the protection step comprises a mono-C ⁇ -C 6 -alkyloxytritylation or a bis-C Ce-alkyloxytritylation of the primary hydroxyl function in the 6'-O-position of glucose.
  • the reductive-ring-closure is obtained using a reducing agent, and more preferably the reductive-ring-closure is obtained under radical- induced reductive conditions using a radical initiator and a reducing agent.
  • the removed carbon atom is oxidated into formic acid.
  • the oxidative cleavage of diols using periodate is a fast reaction. With glucopyranoses, however, the oxidative cleavage of diols is an extremely slow reaction and not useful for preparative purposes.
  • the reaction rate can be substantially increased by using Pb(OAc) 4 .
  • the feasibility of this approach has been proven by two examples in the pyrimidine series, i.e. the synthesis of [1 , ,2 , ,3 , ,4 , I 5 , - 13 C 5 , 6- 3 C, 1 ,3- 15 N 2 ]-5'-0-MMTr-uridine in six reaction steps starting from D- [ 13 C 6 ]-glucose and [6- 13 C, 1 ,3- 15 N 2 ]-uracil in a total yield of 44% and the synthesis of [1 , f 2 , ,3 , ,4 , ,5'- 13 C 5 , 6- 13 C, 1 ,3,NH 2 - 5 N 3 ]-5'-0-MMTr-N 4 -benzoylcytidine using [6- 13 C, 1 ,3-NH 2 - 15 N 3 ]-N 6 -benzoylcytosine
  • the reductive ring closure reaction using tri-n-butyltin hydride as reducing agent and AIBN as radical initiator in dioxane to give 7 is at present the reaction step in this scheme with the lowest yield (62%).
  • the introduction of the monomethoxytrityl group in the 6'-0-position before carrying out the final reactions, is preferred for the stereochemical outcome of the carbon-carbon bond forming reaction and for facilitating the work-up procedure.
  • the cytosine base was protected with a benzoyl group (90% yield) and the 6'-hydroxyl group was protected with a monomethoxytrityl group (83% yield).
  • Reaction of [1 ' l 2',3 , ,4' ) 5 , ,6 , - 13 C 6 ]-(6 , -0-MMTr- ⁇ -D-glucopyranosyl)- [6- 13 C,1 ,3,NH 2 - 15 N 3 ]- N 4 -benzoylcytosine with Pb(OAc) in dichloromethane gave the oxidized ring opened nucleoside in 92% yield.
  • the ribose ring was obtained by reacting the dialdehyde with Bu 3 SnH and AIBN in dioxane in 54% yield.
  • silylated N 6 -benzoyladenine was reacted with penta-O-acetyl- D-glucose in dichloromethane using SnCI 4 , after which the protecting groups were removed in basic medium, leaving 9-[ ⁇ -D-glucopyranosyl)adenine as a crystalline material.
  • the adenine base was protected with a benzoyl group and the 6'-hydroxyl group was protected with a monomethoxytrityl group. This gave the starting material for the two-step ring contraction reaction.
  • guanine nucleoside For the synthesis of the guanine nucleoside, a transglycosylation reaction starting from tri-O-acetyl-uridine is preferred. Therefore a mixture of tri-O-acetyl-uridine and N 2 - isobutyrylguanine are treated respectively with BSA and trimethylsilyl triflate under reflux.
  • the reductive ring closure can likewise be carried out with other reducing agents such as sodium hypophosphite (NaH 2 PO 2 .H 2 O) or Sm(ll)l 2 .
  • NaH 2 PO 2 .H 2 O sodium hypophosphite
  • Sm(ll)l 2 Sm(ll)l 2 .
  • This method is used for the stereocontrolled formation of cyclic vicinal diols.
  • the first examples of such intramolecular pinacol couplings using transition metal catalysts have been described by Kagan et al. and Molander and Kenny. The following procedure is given only as an example of alternative ring closure procedures.
  • the invention further relates to the synthesis of labeled ribonucleosides obtainable via the method according to the invention, wherein the ribonucleosides are naturally occurring nucleosides analogues. More preferably, the ribonucleosides are chosen from adenosine, guanosine, cytidine, uridine and 5-methyluridine, inosine, ⁇ -methyladenosine, ⁇ . ⁇ / 6 - dimethyladenosine, ⁇ -methylguanosine, ⁇ -dimethylguanosine, ⁇ methylcytidine and
  • the ribonucleosides obtained can be further functionalized into building blocks for the chemical or enzymatic synthesis of labeled RNA.
  • the ribonucleosides can be deoxygenated at the 2'-position according to Robins et al. 5'-0-Dimethoxytritylation and phosphitylation lead to the DNA phosphoramidites.
  • the labeled compounds synthesized according to the method of the invention can be used for NMR applications, as well as, in mass spectrometry and diagnostics, i
  • NMR spectra were recorded on a Varian, Gemini 200 spectrometer ( H-200 MHz, 13 C 50 MHz). All NH/OH protons were assigned by exchange with D 2 O. Mass spectra were recorded on a Kratos Concept 1 H mass spectrometer (Ms, LSIMS [m/z] (%)); Samples were dissolved in glycerol (Gly) / thioglycerol (Thgly) / m-nitrobenzyl alcohol (NBA) and the secondary ions were accelerated at 6 kV. Scans were performed at 10 sec / decade).
  • Exact mass measurements were performed on a quadrupole - time of flight mass spectrometer (Q-Tof-2, Micromass, Manchester, UK) equipped with a standard electrospray ionization (ESI)interface. Samples were infused in a 2-propanol : water (1 : 1 ) mixture at 3 mUmin. TLC was performed with TLC aluminum sheets (Merck, Silica gel 60 F 25 ) and silica (200 - 425 mesh) was used for column chromatography. Melting points (mp [°C]) were determined with a B ⁇ chi-SMP - 20 capillary melting point apparatus. For all reactions dry (molecular sieve) analytical grade solvents were used. Solvents for column chromatography were used without any further purification.
  • Tri-n-butyltin hydride (0.43 g, 0.4 mL, 1.25 mmol) is added via a septum.
  • the reaction mixture is heated to 90°C.
  • N 6 -Benzoyl-9-(2'.3'.4'.6'-tetraacetyl- ⁇ -D- ⁇ lucopyranosv ⁇ adenine Yield: 4.25 g (74 %); R, (ethyl acetate): 0.47; mp: 168-169 Q C (methanol; lit: 171°C, ethanol) 15
  • N 4 -Benzoyl-(2'.3'.4'.6'-tetraacetyl- ⁇ -D- ⁇ lucopyranosvncvtosine Yield: 7.2 g (94 %); R, (ethyl acetate): 0.48; mp: 258-260 9 C (methanol; lit: 260 9 C) 15
  • TMSCI (1.80 g, 2 mL, 16 mmol) was added to a solution of 9-( ⁇ -D- glucopyranosyl)adenine (0.95 g, 3.2 mmol) or ( ⁇ -D-glucopyranosyl)cytosine (0.85 g, 3.2 mmol), respectively, in pyridine (8 mL).
  • pyridine 8 mL
  • the mixture was stirred at ambient temperature for 15 min.
  • benzoyl chloride (0.91 g, 0.76 mL, 6.4 mmol
  • the reaction mixture was cooled to 0°C, ice water (10 mL) was added and after stirring for 15 min an addition of comp, aqueous NH 3 . (20 mL) followed.
  • the solvent was removed in vacuo after stirring for another 30 min at ambient temperature.
  • N 4 -Benzoyl-1-( ⁇ -D-qlucopyranosyl)cvtosine Yield: 1.04 g (90 %); R f (ethyl acetate) 0.52, mp:
  • A,C-dialdehyde (1 mmol), respectively, was dissolved in absolute dioxane (8 mL) under a nitrogen atmosphere. Tri-n-butyltin hydride (0.43 g, 0.4 mL, 1.25 mmol) is added via a septum. The reaction mixture is heated to 90°C. Via the septum a solution of AIBN (0.02 g, 0.12 mmol) in dioxane (2 mL) is added. Foam is formed, after stirring for 30 min at 90°C the reaction mixture was checked with TLC (CH 2 CI 2 /MeOH 95 : 5).
  • Tate S.-i., Ono, A., Kainosho, M. (1995) J. Magn. Res. ser B, 106, 89-91. Szyperski, T., Ono, A., Fernandez, C, Iwai, H., Tate, S.-i., W ⁇ thrich, K., Kainosho, M.

Abstract

The invention relates to a method for the chemical preparation of labeled nucleosides via an oxidative-ring-opening step and a reductive-ring-closure step starting from a labeled D-glucose nucleoside resulting in the corresponding D-ribose-nucleoside by removing the carbon atom 3 on the glucose and comprising the steps of: - a protection of the sugar ring hydroxyl groups, - a sugar-base condensation, whereby the base is a purine or a pyrimidine, - a deprotection of the sugar ring hydroxyl groups, - an oxidative-ring-opening and removal of the carbon atom 3, and - a reductive-ring-closure resulting in labeled D-ribose-nucleoside. The invention further relates to a compound obtainable via the method according to the invention having the formula selected from [13C,15N] labeled 6'-O-mono- or 6'-O-bis-C¿1?-C6-alkyloxytrityl-D-glucopyranosyl nucleosides, or [?13C,15¿N] labeled tetra-O-acetyl-D-glucopyranosyl nucleosides or [13C,15N] labeled glucopyranosyl nucleosides.

Description

Labeled nucleosides and method for their preparation
The invention relates to a method for the chemical preparation of labeled nucleosides and to the nucleotides obtainable by said method. A bottleneck in NMR research on nucleic acids structures and dynamics is the availability of isotopically labeled materials in larger amounts and at a reasonable cost. 13C/15N labeled nucleic acids can be obtained by an enzymatic approach, in a chemical way or by a combination of both1. 13C/15N labeled ribomononucleotides can be isolated from bacterial cells grown in isotopically enriched media. These mononucleotides are then converted to their triphosphates using chemical or enzymatic phosphorylation. The labeled nucleoside-5'-triphosphates are then used to prepare RNA from synthetic DNA templates by in vitro transcription with T7 RNA polymerase2. The yield of labeled monomers isolated from the cultures as a mixture of four nucleotides is about 4-5%. The conversion of isotopically labeled glucose into nucleotides in a single coupled enzymatic reaction is a much more efficient process3. Over a gram of isotopically labeled ribomononucleotides can be obtained from 1 gram of glucose.
This method allows the large-scale preparation of uniformly isotopically labeled RNA. However, the synthesis of isotopically labeled DNA in sufficient quantity for structural analysis by NMR, is less obvious. The abundance of DNA in cells is only about 15% of that of RNA. A procedure for the enzymatic synthesis of uniformly 13C and 15N labeled DNA oligonucleotides has been developed only recently4. Enzymatic hydrolysis of DNA of bacteria grown with 15N- and 3C enriched nutrients deliver the deoxymononucleotides, which are enzymatically phosphorylated to the triphosphates. The labeled deoxynucleotide-5'-triphosphates are incorporated into oligonucleotides using a 3'-5' exonuclease-deficient mutant of Klenow fragment of DNA polymerase I and a DNA template linked to a primer. Region-specific isotopic enrichment was also described using mutated Klenow DNA polymerase and a hairpin template5. This method was followed by a more efficient procedure using Taq DNA polymerase6. Louis et al. described a method for the large scale preparation of uniformly isotope labeled DNA by a) the growth of a suitable plasmid harboring multiple copies of the described oligonucleotide in a medium based on 5N and 13C nutrients or b) a polymerase chain reaction with 15N- and/or 13C labeled deoxynucleoside triphosphates7.
In comparison with the enzymatic methods, the chemical methods need more technical expertise8 The chemical synthesis, however, is much more flexible and allows the preparation of virtually all-possible isotopomeric nucleosides and site specific labeled oligomers9. Specific labeling will allow more accurate NMR parameters to be obtained. The chemical approach, likewise, opens the possibility to obtain labeled modified nucleosides and oligonucleotides. A more efficient and less costly chemical synthesis would have considerable advantages over the enzymatic approach. The key step in the chemical preparation of fully labeled nucleotides is the synthesis of protected [13C5]-D-ribose, which starts from the readily available [13C6]-D-glucose10"12. The overall yield of this conversion is 40%. The [13C5]-1 ,2,3,5-tetra-0-acyl-α,β-D-ribofuranose is then converted into the individual protected nucleosides by Vorbruggen condensation13, deprotection and tritylation reactions. The disadvantages of the published methods are the multiple steps needed to convert [13C6]- D-glucose into [13C5]- D-ribose. The reason for this is that one of the carbon atoms (C-3) of D-glucose has to be inverted in configuration while another carbon atom (C-6) has to be removed (Figure 1 : Literature methods use the conversion of glucopyranose to glucofuranose to invert the configuration at C-3 and remove C-6 in an oxidative way). This is accomplished by the conversion of glucopyranose to glucofuranose. The published methods differ from each other by a) first inversion of configuration by a PDC-NaBH4 reaction and then oxidative cleavage of the side chain10; b) first shortening of the side chain by a NalO4-NaBH4 reaction followed by inversion of configuration using a nucleophilic substitution reaction11; c) a one pot procedure to oxidative cleave the diol and reduce simultaneously both the 3-keto function and the 6-aldehyde group12.
Surprisingly, an economically much more profitable approach would be the direct removal of the carbon atom with the wrong configuration i.e. carbon atom 3 of D-glucose. This can be achieved by starting with a glucopyranose nucleoside via an oxidative ring opening - reductive ring closure procedure that removes the carbon-atom 3 (Scheme A). In scheme A i is Ac2O, pyr, 0 °C, 97%; ii is [6- 3C, 1 ,3-15N2]-uracil, CICH2CH2CI, BSA,
TMSOTf, Δ, 87.5 %; iii is NH3, MeOH, 98 %; iv is MMTrCI, pyr, Et3N, 92%; v is Pb( OAc)4, CH CI2, 90 %; vi is Bu3SnH, AIBN, dioxane, 62%. The isotopically labeled C-atoms are marked as • and the N-atoms are indicated with *. SCHEME A
Figure imgf000004_0001
The invention relates therefor to a method for the chemical preparation of labeled nucleosides via an oxidative-ring-opening step and a reductive-ring-closure step starting from a labeled D-glucose nucleoside resulting in the corresponding D-ribose-nucleoside by removing the carbon atom 3 on the glucose. In a preferred embodiment the method according to the invention starting from partially or fully labeled D-glucose comprises the steps of:
- a protection of the sugar ring hydroxyl groups,
- a sugar-base condensation, whereby the base is a purine or a pyrimidine,
- a deprotection of the sugar ring hydroxyl groups, - an oxidative-ring-opening and removal of the carbon atom 3, and
- a reductive-ring-closure resulting in labeled D-ribose-nucleoside.
More preferably, the labeled glucose is from the group consisting of [13C6]-D-glucose or a partially labeled D-glucose, and the purine or pyrimidine of step 2 is fully or partially labeled In a more preferred embodiment the deprotection of the sugar ring hydroxyl groups is followed by a protection step of the primary OH-group, wherein the primary OH-group is protected as a trityl or silyl ether or by any other protecting group stable to the oxidative-ring- opening and reductive-ring-closure reactions. More preferably, the protection step comprises a mono-Cι-C6-alkyloxytritylation or a bis-C Ce-alkyloxytritylation of the primary hydroxyl function in the 6'-O-position of glucose.
Yet in a more preferred embodiment, the reductive-ring-closure is obtained using a reducing agent, and more preferably the reductive-ring-closure is obtained under radical- induced reductive conditions using a radical initiator and a reducing agent.
The removed carbon atom is oxidated into formic acid. The oxidative cleavage of diols using periodate is a fast reaction. With glucopyranoses, however, the oxidative cleavage of diols is an extremely slow reaction and not useful for preparative purposes.
The reaction rate can be substantially increased by using Pb(OAc)4. The feasibility of this approach has been proven by two examples in the pyrimidine series, i.e. the synthesis of [1 ,,2,,3,,4, I5,-13C5, 6- 3C, 1 ,3-15N2]-5'-0-MMTr-uridine in six reaction steps starting from D- [13C6]-glucose and [6-13C, 1 ,3-15N2]-uracil in a total yield of 44% and the synthesis of [1 , f2,,3,,4,,5'-13C5, 6-13C, 1 ,3,NH2- 5N3]-5'-0-MMTr-N4-benzoylcytidine using [6-13C, 1 ,3-NH2- 15N3]-N6-benzoylcytosine in seven steps and a total yield of 32 %. Due to its shortness and high yield, this reaction scheme can be considered as a considerable improvement over existing methods10"12 making labeled nucleotide material more easily available.The per acetylated [13C6]- D-glucose (2), obtained by reaction of [13C6]- D-glucose (1 ) with acetic anhydride in pyridine was condensed with [6-13C, 1 ,3-15N2]uracii under Vorbruggen conditions in 87.5% yield. Full deprotection of 3 with ammonia in methanol (to 4), followed by monomethoxytritylation of the primary hydroxyl function yielded [V,2',3',4',5',6'- C6]-(6'-0- MMTr-β-D-glucopyranosyl)-[6-13C,1 ,3-15N2]-uracil (5). The yield of the deacetylation reaction is 98% and of the monomethoxytritylation reaction is 92%. The glucose sugar was oxidatively cleaved using Pb(OAc)4 in dichloromethane to give 6 in a yield of 90%. The reductive ring closure reaction using tri-n-butyltin hydride as reducing agent and AIBN as radical initiator in dioxane to give 7 is at present the reaction step in this scheme with the lowest yield (62%). The introduction of the monomethoxytrityl group in the 6'-0-position before carrying out the final reactions, is preferred for the stereochemical outcome of the carbon-carbon bond forming reaction and for facilitating the work-up procedure.
The feasibility of this synthetic scheme for the synthesis of the corresponding labeled cytosine nucleoside 8 has been proven. Silylated [6-13C,1 ,3,NH2-15N3]-N4-benzoylcytosine was reacted with [1',2',3',4',5',6'-13C6]-glucose penta-O-acetate in dichloromethane in the presence of SnCI (99% yield) after which the protecting groups were removed in basic medium (92% yield) leaving [1,,2'l3, I4, l5, >6'-13C6]-(β-D-glucopyranosyl)- [6-13C,1 ,3,NH2-15N3]- cytosine as a crystalline material. The cytosine base was protected with a benzoyl group (90% yield) and the 6'-hydroxyl group was protected with a monomethoxytrityl group (83% yield). Reaction of [1 'l2',3,,4')5,,6,-13C6]-(6,-0-MMTr-β-D-glucopyranosyl)- [6-13C,1 ,3,NH2-15N3]- N4-benzoylcytosine with Pb(OAc) in dichloromethane gave the oxidized ring opened nucleoside in 92% yield. The ribose ring was obtained by reacting the dialdehyde with Bu3SnH and AIBN in dioxane in 54% yield.
In summary, we describe a new synthetic scheme leading to [13C, 15N]-labeled 5'-0- monomethoxytrityl-uridine and 5-0-monomethoxytrityl-N6-benzoylcytidine in six and seven steps respectively from D-[13C6]-glucose in a total yield of 44%, and 32% respectively. Given the observation that 1 can be converted into 4 in a one pot procedure and that 6 is an intermediate that does not need complete isolation, the conversion of 1 to 7 can be considered as a three-step reaction. This method has the advantage over previously described synthetic schemes because of a) its shortness (for uridine: ref. 10: 13 reactions, ref. 1 1 : 1 1 reactions, ref. 12: 9 reactions), b) simple protecting group manipulation giving the monomethoxytritylated nucleoside in a straightforward way and c) a total yield which is better10,11 than or similar12 to existing literature procedures. The feasibility of this synthetic scheme for the synthesis of purine nucleosides has been proven, using adenine substituted compounds as example.
Thus, silylated N6-benzoyladenine was reacted with penta-O-acetyl- D-glucose in dichloromethane using SnCI4, after which the protecting groups were removed in basic medium, leaving 9-[β-D-glucopyranosyl)adenine as a crystalline material. The adenine base was protected with a benzoyl group and the 6'-hydroxyl group was protected with a monomethoxytrityl group. This gave the starting material for the two-step ring contraction reaction. Reaction of 6'-0-monomethoxytrityl-N6-benzoyl-9-(β-D-glucopyranosyl)adenine with Pb(OAc) in dichloromethane gave the oxidized material in 88%. The ribose ring was obtained by reacting the dialdehyde with Bu3SnH and AIBN in dioxane. These key reactions of the synthetic procedure, yielding 5'-0-monomethoxytrityl-N6-benzoyladenosine are depicted in Figure 2, wherein B is N6-benzoyladenine, i is Pb(OAc)4, CH2CI2 and ii is Bu3SnH, AIBN, dioxane and the yields of the individual reactions are given in Table 1.
For the synthesis of the guanine nucleoside, a transglycosylation reaction starting from tri-O-acetyl-uridine is preferred. Therefore a mixture of tri-O-acetyl-uridine and N2- isobutyrylguanine are treated respectively with BSA and trimethylsilyl triflate under reflux.
As an alternative to tin hydride, the reductive ring closure can likewise be carried out with other reducing agents such as sodium hypophosphite (NaH2PO2.H2O) or Sm(ll)l2. This method is used for the stereocontrolled formation of cyclic vicinal diols. The first examples of such intramolecular pinacol couplings using transition metal catalysts have been described by Kagan et al. and Molander and Kenny. The following procedure is given only as an example of alternative ring closure procedures.
In a typical procedure a solution of Sml2 in THF (0.1 M, 10.8 mL) was cooled to -78SC. Under nitrogen atmosphere a mixture of the Uracil-dialdehyde (0.222g, 0.431 mmol) in THF (10 mL) and THF/t-BuOH (1.1 mL, 1 M) was added over a period of 15 min. After stirring the reaction mixture at -78QC for one hour the temperature was slowly increased to room temperature over a period of 2 hours. After addition of sodium bicarbonate (50 mL) the white slurry was extracted with ethyl acetate (5 x 60 mL). The organic phase was washed with 10 % Na2S O3 (50 mL), dried over Na2SO , and after the solvent was removed, the residue was purified by column chromatography (silica, 15 x 2 cm, CH2CI (80 ml), followed by a gradient from CH2CI2 to CH2CI2/MeOH = 95 : 5). MMT-Uridine was obtained in 64 % yield slightly contaminated with enantiomeric impurities, which were removed by HPLC.
The invention further relates to the synthesis of labeled ribonucleosides obtainable via the method according to the invention, wherein the ribonucleosides are naturally occurring nucleosides analogues. More preferably, the ribonucleosides are chosen from adenosine, guanosine, cytidine, uridine and 5-methyluridine, inosine, Λ -methyladenosine, Λ^.Λ/6- dimethyladenosine, Λ -methylguanosine, Λ^^-dimethylguanosine, Λ methylcytidine and
Figure imgf000008_0001
The ribonucleosides obtained can be further functionalized into building blocks for the chemical or enzymatic synthesis of labeled RNA.
To obtain deoxyπbonucleosides selectively, the ribonucleosides can be deoxygenated at the 2'-position according to Robins et al. 5'-0-Dimethoxytritylation and phosphitylation lead to the DNA phosphoramidites.
The labeled compounds synthesized according to the method of the invention can be used for NMR applications, as well as, in mass spectrometry and diagnostics, i
Table 1 : Yield of the reactions used for the synthesis of the protected ribose nucleosides
Figure imgf000008_0002
* reactions are carried out with N -benzoyladenine and N benzoylcytosine ** as well the adenine as cytosine base are protected with a benzoyl group using the transient protection procedure EXPERIMENTAL
NMR spectra were recorded on a Varian, Gemini 200 spectrometer ( H-200 MHz, 13C 50 MHz). All NH/OH protons were assigned by exchange with D2O. Mass spectra were recorded on a Kratos Concept 1 H mass spectrometer (Ms, LSIMS [m/z] (%)); Samples were dissolved in glycerol (Gly) / thioglycerol (Thgly) / m-nitrobenzyl alcohol (NBA) and the secondary ions were accelerated at 6 kV. Scans were performed at 10 sec / decade). Exact mass measurements were performed on a quadrupole - time of flight mass spectrometer (Q-Tof-2, Micromass, Manchester, UK) equipped with a standard electrospray ionization (ESI)interface. Samples were infused in a 2-propanol : water (1 : 1 ) mixture at 3 mUmin. TLC was performed with TLC aluminum sheets (Merck, Silica gel 60 F25 ) and silica (200 - 425 mesh) was used for column chromatography. Melting points (mp [°C]) were determined with a Bϋchi-SMP - 20 capillary melting point apparatus. For all reactions dry (molecular sieve) analytical grade solvents were used. Solvents for column chromatography were used without any further purification.
PREPARATION OF FULLY LABELED GLUCOSE PENTA-O-ACETATE: After cooling pyridine (20 mL) to 0 9C, acetic anhydride (15 g, 14 mL, 0.15 mmol) was added. The fully labeled glucose (3.0 g, 0.016 mmol) was added in small portions at 09 C. The reaction temperature was slowly allowed to come to ambient temperature and stirred at room temperature overnight. After addition of water (60 mL) an oil is formed, which turns solid on scrapping. The resulting precipitate is filtered off and recrystallized from water. The ratio of α : β enantiomer is 1 : 1 (13C NMR).
n ,2.3.4.5.6-13CR1-Glucose penta-O-acetate: Yield: 6.20 g (97 %) R, (CH2CI2/MeOH = 95 : 5): 0.63; mp: 1 10 - 1 12gC (H2O); 1H-NMR (200 MHz, CDCI3):δ = 2.01 - 2.18 (5 x 3H Ac), 3.74 -
4.81 (4H, m, 2 x H-6', H5', H3'), 5.44-5.56 (1 H, m, H4'), 5.28, 6.13 (1 H, d x d, J1 = 167 Hz, J2
8.6 Hz; H1 ' β-isomer), 5.88, 6.76 (1 H, d x m, J1 = 167 Hz; H1 ' α-isomer); 13C-NMR (50 MHz, CDCI3): δ =
20.2-20.5 (5 x CH3 Ac), 169.5 - 170.7 (5 x C=O Ac), 60.9, 61.8 (d, J= 44 Hz, CH2-6'), 67.2 - 71.0 (m, 3 CH, CH-4',2',3'), 72.7 (t, J= 44 Hz, CH-5'), 88.0, 88,6 (d, J= 44 Hz, CH-1 'α), 91.4,
92.0 (d, J= 44 Hz, CH-1 'β); MS (LSIMS; Thgly; m/z (%)): 337 (73.3) [M + H]+. GLYCOSYLATION REACTION OF URACIL WITH FULLY LABELED GLUCOSE PENTA-O- ACETATE:
To a suspension of [6-13C,1 ,3-15N2]-uracil (0.96 g, 8.32 mmol) and [13C6]-glucosepenta-0- acetate (3.3 g, 8.32 mmol) in dichloroethane (40 mL) BSA (4.8 mL, 20 mmol) was added. The mixture was stirred under nitrogen at ambient temperature for 20 min to give a clear, colorless solution. After addition of TMSOTf (3.60 mL, 20 mmol) under nitrogen the reaction mixture was heated under reflux for 2 h. After cooling to ambient temperature the resultant brown mixture was evaporated in vacuo. The resulted oil was diluted in ethyl acetate (200 mL) and washed with NaHCO3 (150 mL) and brine NaCI-solution (2 x 100 mL). After drying over Na2SO4 and evaporating the solvent, the resultant oil was purified by column chromatography (silica, 24 x 3 cm, ethyl acetate/petroleum ether = 2 : 1).
ri '.2'.3'.4'.5'.6'-13CR1-(2'.3'.4'.6'-Tetra-Q-acetyl-β-D-αlucopyranosyl)-uracil: Yield: 3.17 g (85 %); R» (ethyl acetate/petrol ether = 2 : 1 ): 0.34; mp: 152 -154 °C (EtOH°); H-NMR (500 MHz, CDCI3):δ = 2.00 - 2.09 (4 x 3H, 4 x CH3 Ac), 3.92 (1 H, J° = 162 Hz, H5'), 4.11 - 4.29 (2H, J°H = 162 Hz, 2 x H6'), 5.15 (2H, J3H = 162 Hz, H3\ H4'), 5.38 (1 H, ./ = 162 Hz, 7 = 5 Hz, H2'), 5.81 (1 H, d, J = 8.2 Hz, H-5), 5.85 (1 H, J°H = 162 Hz, ^H = 9 Hz, H1 '), 7.33 (1 H, d, J = 8.2 Hz, 6-H), 9.51 (1 H, ex, s, br, NH); 13C-NMR (125.6 MHz, CDCI3): δ = 20.2, 20.3, 20.4, 20.6 (4 x CH3 Ac), 61.5 (d, J= 43 Hz, CH6'), 67.8 (t, J= 43 Hz, CH4'), 69.3 (t, J= 43 Hz, CH2'), 72.7 (t, J= 43 Hz, CH3'), 75.0 (t, J= 43 Hz, CH5'), 80.0 (d, J = 43 Hz, CH1 '), 103.8 (s, 5-CH), 139.1 (s, 6-CH), 150.5 (s, 2-C), 162.7 (s, 4-C), 169.5, 169.6, 169.8, 170.5 (4 x C=O Ac); MS (LSIMS; Thgly; m/z (%)): 1 15 (55), 175 (100), 337 (48) [Glue + H]+, 449 (19) [M + H]+; Exact mass: C^C ' H^NaOn: Calc: 449.1499; Found: 449.1458.
ri '.2'.3'.4'.5'.6'-13CRl-(2'.3,.4'.6'-Tetraacetyl-β-D-glucopyranosyl)-f6-13C.1.3-15N?l-uracil: Yield: 3.29 g (87.5 %); R, (ethyl acetate/petrol ether = 2 : 1 ): 0.34; mp: 153 - 155 °C (EtOH); 1H-NMR (500 MHz, CDCI3): δ = 2.00 - 2.09 (4 x 3H, 4 x CH3 Ac), 3.92 (1 H, J°H = 162 Hz, H5'), 4.1 1 - 4.29 (2H, ^" = 162 Hz, 2 x H6'), 5.15 (2H, ^ = 162 Hz, H3', H4'), 5.38 (1 H, J°H = 162 Hz, fH = 5 Hz, H2'), 5.81 (1 H, m, H-5), 5.85 (1 H, = 162 Hz, J = 9 Hz, H1 '), 7.36 (1 H, J°H = 182 Hz, ^" = 8 Hz, 6-H), 9.1 1 , (1 H, ex, d, br, J = 90 Hz, NH); 13C-NMR (125.6 MHz, CDCI3): δ= 20.2, 20.3, 20.4, 20.6 (4 x CH3 Ac), 61.5 (d, J= 43 Hz, CH6'), 67.8 (t, J= 43 Hz, CH4'), 69.3 (t, J= 43 Hz, CH2'), 72.7 (t,
J= 43 Hz, CH3'), 75.0 (t, J= 43 Hz, CH5'), 80.3 (d x d, J1 = 14.6 Hz, J2 = 45 Hz, CH1 '), 103.7 (d x d, J = 14.6 Hz, = 66 Hz, 5-CH), 139.2 (d, J= 14.6 Hz, 6-CH), 150.5 ((t), J = 1 1 Hz, 2-C), 162.9 (d, J = 1 1 Hz, 4-C), 169.5, 169.6, 169.8, 170.5 (4 x C=O Ac); MS (LSIMS; Thgly; m/z (%)): 1 15 (62), 175 (100), 337 (30) [Glue + H]+, 452 (6) [M + H]+; Exact Mass:
CιιC; H23N * Oιι: Calc: 452.1473; Found: 452.1510.
FULL DEPROTECTION - GENERAL PROCEDURE:
A solution of the tetra-O-acetyl protected nucleoside U (10 mmol) in NH3 / MeOH (20 mL) was stirred overnight at ambient temperature. After removal of the solvent in vacuo the precipitate was recrystallized from dichloromethane.
ri '.2'.3'.4'.5'.6'-13CRl-fβ-D-Glucopyranosyl)-uracil: Yield: 2.69 9(96 %) R, (ethyl acetate): 0.1 ; mp: 201SC (MeOH); 1H-NMR (500 MHz, DMSO-d6):δ = 3.14 (1 H, t, . * = 162 Hz, ^" = 5 Hz, H4'), 3.25 - 3.32 (2H, J° = 162 Hz, H2', H3'), 3.35 - 3.45 (2H, J°H = 162 Hz, H5\ H6'), 3.65 (1 H, <fH = 162 Hz, H6'), 5.29 (1 H, fH = 160 Hz, = 9 Hz, H1 '), 5.62 (1 H, d, J = 8 Hz, H- 5), 7.64 (1 H, d, j"H = 8 Hz, 6-H), 4.04 (1 H, d, br, ex, J = 5.2 Hz, OH), 4.52, (1 H, t, br, ex, J = 5.6 Hz, 6'-OH), 5.01 (1 H, d, br, ex, J = 5.2 Hz, OH), 5.14, (1 H, d, br, ex, J = 5.2 Hz, OH), 10.99 (1 H, s, br, ex, NH); 13C-NMR (125.6 MHz, DMSO-d6): δ = 60.9 (d, J= 43 Hz, CH6"), 69.6 (t, J= 43 Hz, CH4'), 70.8 (t, J= 43 Hz, CH2'), 76.9 (t, J= 43 Hz, CH3'), 79.9 (t, J= 43 Hz, CH5'), 82.5 (d x d, J1 = 14.6 Hz, J3 = 45 Hz, CH1 '), 102.1 (s, 5-CH), 141.7 (s, 6-CH), 151.2 (s, 2-C), 163.3 (s, 4-C); MS (LSIMS; Gly.TFA; m/z (%)): 91 (100), 281 (9) [M + H]+; Exact Mass:
C4C* H15N2O7: Calc: 281.1081 ; Found: 281.1094.
π '■2,.3'.4'.5'.6'- 3CRl-(β-D-Glucopyranosyl)-f6-13C. 1.3-15N,1-uracil: Yield: 2.77 9(98 %) R, (ethyl acetate): 0.1 ; mp: 202°C (MeOH); 1H-NMR (500 MHz, DMSO-d6):δ = 3.14 (1 H, t, JCH = 162 Hz, J*H = 5 Hz, H4'), 3.25 - 3.32 (2H, f = 162 Hz, H2", H3'), 3.35 - 3.45 (2H, J° = 162 Hz, H5\ H6'), 3.65 (1 H, J°H = 162 Hz, H6'), 5.29 (1 H, J°H = 160 Hz, J = 9 Hz, H1 '), 5.61 (1 H, m, H-5), 7.60 (1 H, J H = 182 Hz, ^" = 8 Hz, 6-H), 4.04 (1 H, d, br, ex, J = 5.2 Hz, OH), 4.52, (1 H, t, br, ex, J = 5.6 Hz, 6'-OH), 5.01 (1 H, d, br, ex, J = 5.2 Hz, OH), 5.14 (1 H, d, br, ex, J = 5.2 Hz, OH), 11.4 (1 H, d, br, ex J = 90 Hz, NH); 13C-NMR (125.6 MHz, DMSO-d6): δ = 60.9 (d, J= 43 Hz, CH6'), 69.6 (t, J-. 43 Hz, CH4'), 70.8 (t, J= 43 Hz, CH2'), 76.9 (t, J= 43 Hz, CH3'), 79.9 (t, J= 43 Hz, CH5'), 82.5 (d x d, J1 = 14.6 Hz, J2 = 45 Hz, CH1 '), 101.3 (d x d, j1= 14.6 Hz, 66 Hz, 5-CH), 141.0 (d, J= 14.6 Hz, 6-CH), 151.0 ((t), J = 11 Hz, 2-C), 163.3 (d, j = 11 Hz, 4-C); MS (LSIMS; Gly.TFA; m/z (%)): 284 (5) [M + H]+; Exact Mass: C3C H3ON O8: Calc: 284.1055; Found: 284.1061.
INTRODUCTION OF MONOMETHOXYTRITYL IN THE 6' POSITION: GENERAL PROCEDURE:
The mixture of nucleoside U (3.5 mmol), and MMTCI (2.16 g, 7.0 mmol) in pyridine (20 mL) and triethylamine (5 mL) was stirred in an inert atmosphere at ambient temperature for 18 h. After removing the solvent in vacuo the resulted oil was coevaporated with toluene (4x2 mL). The resultant foam was purified by column chromatography. (silica, 15x3 cm, CH2CI2/MeOH =9:1).
fl'^'.S' '.S'.e'-^C^-e'-O-Monomethoxytrityl-fβ-D-glucopyranosvD-uracil: Yield: 1.68 g (85 %); R, (CH2CI2/MeOH = 9 : 1): 0.31; mp: 168 - 170SC; 1H-NMR (500 MHz, DMSO-d6):δ = 3.63 (3H, s,CH3O), 3.00 -3.05(1 H, m, J=H= 162 Hz, H5'), 3.18 - 3.30 (2H, m, ^=162 Hz, 2 x H6'), 3.45 (1H, (t), J=H= 162 Hz, SH= 5Hz, H4'), 3.53 (1H, (t), J°H= 162 Hz, ^H= 5 Hz, H3'), 5.38 (1 H, f = 160 Hz, j"H = 9 Hz, H1 '), 5.72 (1 H, d, J = 8.2 Hz, H-5), 5.05 (1 H, br, ex, OH), 5.28, (1H, br, ex, OH), 5.40 (1H, br, ex, OH), 6.87 - 7.73 (m, 15 H, H-Ar MMT + 6-H), 11.4 (1H, s, br, ex, NH); 13C-NMR (125.6 MHz, DMSO-d6): δ = 55.1 (s, CH3O), 63.7 (d, J= 43 Hz, CH6'), 69.6 (t, J= 43 Hz, CH4'), 70.6 (t, J= 43 Hz, CH2'), 76.6 (t, J= 43 Hz, CH3"), 77.9 (t, J= 43 Hz, CH5'), 82.4 (d, J = 45 Hz, CH1'), 85.5 (C, MMT), 102.0 (s, 5-CH), 113.2 (s, 2CH, AA'BB', MMT), 126.9-130.3 (CAr, MMT), 135.4 (s, 1C, AA'BB', MMT), 141.4 (s, 6-CH), 144.7 (s, 2 x 1C, MMT), 151.0 (s, 2-C), 158.3 (s, 4C, AA'BB', MMT), 163.2 (s, 4-C); MS (LSIMS; Thgly; m/z): 273 (100) [MMT]+, 575 (10) [M + Na]+ 597 (16) [M - H + 2Na]+; Exact Mass: C24C6 *H3oN2O8Na: Calc: 575.2102; Found: 575.2116
ri'.2'.3'.4'.5'.6'-13Cfi1-6'-0-Monomethoxytrityl-(β-D-αlucopyranosvn-r6-13C.1.3-15N?1-uracil: Yield: 1.8 g (92 %); R, (CH2CI2/MeOH = 9 : 1): 0.31; mp: 168 - 170SC; 1H-NMR (500 MHz, DMSO-d6):δ = 3.63 (3H, s, CH3O), 3.00 - 3.05 (1 H, m, °H = 162 Hz, H5'), 3.18 - 3.30 (2H, m, ^=162 Hz, 2 x H6'), 3.45 (1H, (t), "= 162 Hz, HH = 5Hz, H4'), 3.53 (1H, (t), ^=162 Hz, = 5 Hz, H3'), 5.38 (1 H, °H = 160 Hz, ™ = 9 Hz, H1 '), 5.72 (1 H, m, H-5), 5.04 (1 H, br, ex, OH), 5.26, (1H, br, ex, OH), 5.41 (1H, br, ex, OH), 6.87 - 7.42 (m, 15 H, H-Ar MMT + 6-H), 11.4 (1H, ex, d, br, J = 90 Hz, NH); 13C-NMR (125.6 MHz, DMSO-d6): δ = 55.1 (s, CH3O), 63.7 (d, J= 43 Hz, CH6'), 69.6 (t, J= 43 Hz, CH4'), 70.6 (t, J= 43 Hz, CH2'), 76.6 (t, J= 43 Hz, CH3'), 77.9 (t, J= 43 Hz, CH5'), 82.3, 82.6 (d x d, J1 = 14.6 Hz, J2 = 45 Hz, CH1 '), 85.8 (C, MMT), 101.3 (d x d, J1= 14.6 Hz, = 66 Hz, 5-CH), 1 13.3 (s, 2CH, AA'BB', MMT), 126.9- 130.3 (CAr, MMT), 135.4 (s, 1 C, AA'BB', MMT), 141.4 (d, J= 14.6 Hz, 6-CH), 144.7 (s, 2 x 1C, MMT), 151.0 ((t), J = 11 Hz, 2-C), 158.3 (s, 4C, AA'BB", MMT), 163.3 (d, J = 11 Hz, 4-C); MS (LSIMS; Thgly; m/z): 273 (100) [MMT]+, 578 (2) [M + Na]+ 600 (12) [M - H + 2Na]+; Exact
Mass: C23C* H29N * O8Na2: Calc: 600.1895; Found: 600.1864.
OXIDATIVE RING OPENING OF U: GENERAL PROCEDURE:
To a solution of 6'O-MMT nucleoside U (1 mmol) in absolute dichloromethane (10 mL), Pb(OAc) (1.33 g, 3 mmol) is added under nitrogen at ambient temperature. The solution gets warm and turns yellow." After 2 h a colorless precipitate of Pb(OAc)2 is formed. Stirring is continued overnight. After removing the solvent on a rotavapor the residue is purified by column chromatography (silica, 10 x 2 cm, C^CI^MeOH = 95 : 5). MS verified the structure of the resulted colorless foams because of the complicated equilibrium observed in the NMR14.
n '.2'.3'.4'.5'-13Cc;1-5'-0-Monomethoxythtyl-uridine dialdehvde: Yield: 0.43 g (89 %); R, (CH2Cl2/MeOH = 9 : 1) 0.44, MS (ESI; m/z (%)): 273 (100) [MMTf, 542 (2) [M + Na]+; Exact
Mass: C24C * H26N2OθNa: Calc: 542.1802; Found: 545.1813.
π\2\3'.4'.5'-13C -5'- Monomethox rityl-r6-13C. 1.3-15N?1-uridine dialdehvde: Yield: 0.49 g (90 %); R, (CH2CI2/MeOH = 9 : 1 ) 0.44, MS (ESI; m/z (%)): 273 (100) [MMT]+, 545 (2) [M +
Na]+; Exact Mass: C23C * H26N * O8Na: Calc: 545.1774; Found: 545.1766.
REDUCTIVE RING CLOSURE OF U: GENERAL PROCEDURE:
U-dialdehyde (1 mmol), was dissolved in absolute dioxane (8 mL) under a nitrogen atmosphere.
Tri-n-butyltin hydride (0.43 g, 0.4 mL, 1.25 mmol) is added via a septum. The reaction mixture is heated to 90°C. Via the septum a solution of AIBN (0.02 g, 0.12 mmol) in dioxane (2 mL) is added. Foam is formed, after stirring for 30 min at 90°C the reaction mixture was checked with TLC (CH2CI2/MeOH = 95 : 5). If unreacted aldehyde is monitored on TLC, some more AIBN (0.01 g, 0.06 mmol) and tri-n-butyltin hydride (0.11 g, 0.1 mL, 0.31 mmol) are added and stirring at 90°C is continued for another 60 min. After evaporating the solvent under reduced pressure the residue is purified by column chromatography (silica, 20 x 3 cm, CH2CI2 (100 mL) → CH2CI2/MeOH = 95 : 5).
ri '.2'.3'.4'.5'-13C -5'-Monomethoxytrityl-uridine: 0.34 g, (58 %); R, (CH2CI2/MeOH =95 : 5): 0.41 ; mp: 100 - 105°C (CH2CI2); 1H-NMR (500 MHz, DMSO-d6):δ = 3.56 (3H, s, CH3O), 3.00 - 3.05 (2H, m, J°" = 162 Hz, 2x H5'), 4.00 (1 H, m, <J°H = 162 Hz, H2'), 4.13 (2H, m, • * = 162 Hz, H3', H4'), 5.16 (1 H, br, ex, OH), 5.30 (1 H, d, J = 8 Hz, H-5), 5.51 , (1 H, br, ex, OH), 5.80 (1 H, J3" = 160 Hz, = 6.4 Hz, H1 '), 6.89 - 7.42 (m, 15 H, H-Ar MMT + 6-H), 11.37 (1 H, s, br, ex, NH); 13C-NMR (50 MHz, DMSO-d6): δ = 55.2 (s, CH3O), 63.0 (d, J= 43 Hz, CH5"), 69.6 (t, J= 43 Hz, CH2'), 73.6 (t, J= 43 Hz, CH3'), 82.5 (t, J= 43 Hz, CH4'), 89.0 (d, J = 45 Hz, CH1 '), 86.3 (C, MMT), 101.6 (s, 5-CH), 113.5 (s, 2CH, AA'BB', MMT), 124.1-130.3 (CAr, MMT), 134.8 (s, 1 C, AA'BB", MMT), 140.8 (s, 6-CH), 144.1 , 144.4 (s, 2 x 1 C, MMT), 150.7 (s, 2-C), 158.5 (s, 4C, AA'BB', MMT), 163.3 (s, 4-C); MS (ESI; m/z (%)): 273 (100) [MMT]+, 544
(34) [M + Na]+; Exact Mass: C24C * 5 H28N2O7Na: Calc: 544.1959; Found: 544.1962.
π \2\3'.4'.5'-13C.j1-5'-Monomethoxytrityl-r6-13C. 1.3-15N?1-uridine: 0.34 g, (57 %); R, (CH2CI2 : MeOH =95 : 5): 0.41 ; mp: 100 - 105°C (CH2CI2); 1H-NMR (500 MHz, DMSO-d6): δ = 3.56 (3H, s, CH3O), 3.00 - 3.05 (2H, m, ™ = 162 Hz, 2x H5'), 4.00 (1 H, m, °H = 162 Hz, H2'), 4.13 (2H, m, J°H = 162 Hz, H3\ H4'), 5.16 (1 H, br, ex, OH), 5.30 (1 H, m, H-5), 5.51 , (1 H, br, ex, OH), 5.80 (1 H, . " = 160 Hz, J = 6.4 Hz, H1 '), 6.89 - 7.42 (m, 15 H, H-Ar MMT + 6-H), 11.37 (1 H, d, br, ex, j = 90 Hz, NH); 13C-NMR (50 MHz, DMSO-d6): δ = 55.2 (s, CH3O), 63.0 (d, J= 43 Hz, CH5'), 69.6 (t, j= 43 Hz, CH2'), 73.6 (t, J= 43 Hz, CH3'), 82.5 (t, J= 43 Hz, CH4"), 89.0 (d x d, J = 12 Hz, J2 = 45 Hz, CH1 '), 86.3 (C, MMT), 101.6 (d x d, j1= 14.6 Hz, ^= 66 Hz, 5-CH), 113.5 (s, 2CH, AA'BB", MMT), 124.1 -130.3 (CAr, MMT), 134.8 (s, 1C, AA'BB', MMT), 140.8 (d, J= 14.6 Hz, 6-CH), 144.1 , 144.4 (s, 2 x 1 C, MMT), 150.7 ((t), J = 11 Hz, 2-C), 158.5 (s, 4C, AA'BB', MMT), 163.3 (d, J = 1 1 Hz, 4-C); MS (ESI; m/z (%)): 273 (100) [MMT]+, 547 (34) [M + Na]+; Exact Mass: C23C* 6 H28N O7Na: Calc: 547.1930; Found: 547.1957.
GLYCOSYLATION REACTION OF ADENINE AND CYTOSINE:
To the suspension of N4-benzoylcytosine (2.16 g, 10 mmol) or N6-benzoyladenine (2.40 g, 10 mmol), respectively and glucose penta-O-acetate (4.13 g, 10.6 mmol) in dichloromethane (40 mL) BSA (4.90 mL, 20 mmol) was added. The mixture was stirred under nitrogen at ambient temperature for 20 min resulting in a clear, colorless solution. After addition of SnCI4 (3.52 mL, 30 mmol) under nitrogen the reaction mixture was heated under reflux for 2 h. The resultant brown mixture was cooled to ambient temperature, and after removal of the solvent in vacuo the resulting oil was diluted in ethyl acetate (200 mL) and washed with NaHCO3 (150 mL). The voluminous precipitate of Sn(OH)4 was filtered off and washed with ethyl acetate (5 x 50 mL). The combined organic layers were washed with brine (2 x 100 mL) and dried over Na2SO4. After evaporating the solvent the residual oil was purified by column chromatography (silica, 24 x 3 cm, ethyl acetate/petrol ether = 2 : 1 ).
N6-Benzoyl-9-(2'.3'.4'.6'-tetraacetyl-β-D-αlucopyranosvπadenine: Yield: 4.25 g (74 %); R, (ethyl acetate): 0.47; mp: 168-169QC (methanol; lit: 171°C, ethanol)15
N4-Benzoyl-(2'.3'.4'.6'-tetraacetyl-β-D-αlucopyranosvncvtosine: Yield: 7.2 g (94 %); R, (ethyl acetate): 0.48; mp: 258-2609C (methanol; lit: 2609C)15
FULL DEPROTECTION - GENERAL PROCEDURE:
A solution of the tetra-O-acetyl protected nucleoside A, C (10 mmol) in NH3 / MeOH (20 mL) was stirred overnight at ambient temperature. After removal of the solvent in vacuo the precipitate was recrystallized from dichloromethane.
9-(β-D-Glucopyranosvnadenine: Yield: 3.26 g (94 %); R, (ethyl acetate) 0.1 , mp: 200-203QC
(CH2CI2, lit: 204-206sC)16.
1 -(β-D-Glucopyranosyl)cvtosine : Yield: 2.50 g (92 %); R, (ethyl acetate) 0.1 , mp: 195-196SC (CH2CI2, lit: 197 - 1999C)17.
N-BENZOYLATION OF A AND C VIA TRANSIENT PROTECTION: GENERAL PROCEDURE:
In an inert atmosphere, TMSCI (1.80 g, 2 mL, 16 mmol) was added to a solution of 9-(β-D- glucopyranosyl)adenine (0.95 g, 3.2 mmol) or (β-D-glucopyranosyl)cytosine (0.85 g, 3.2 mmol), respectively, in pyridine (8 mL). The mixture was stirred at ambient temperature for 15 min. After addition of benzoyl chloride (0.91 g, 0.76 mL, 6.4 mmol) stirring was continued for another 3 h. The reaction mixture was cooled to 0°C, ice water (10 mL) was added and after stirring for 15 min an addition of comp, aqueous NH3. (20 mL) followed. The solvent was removed in vacuo after stirring for another 30 min at ambient temperature. The resultant oil was diluted with ethyl acetate (100 mL) and washed with water (20 mL). After drying the organic layer over Na2SO the solvent was evaporated and the resultant oil was treated with MeOH /water (1 : 1 , 14 mL) and ammonium chloride (2 g). Afterwards the mixture was evaporated to dryness and purified by column chromatography (silica, 24 x 3 cm, CH2CI2/MeOH = 9 : 1).
Nβ-Benzoyl-9-fβ-D-qlucopyranosyl)adenine: Yield: 0.96 g (75%); R, (CH2CI2/MeOH = 8 : 2)
0.5, mp: 192 - 1969C; 1H-NMR (200 MHz, DMSO-d6): δ = 3.39 - 3.48 (4H, m, 2 x H6\ H5", H3'), 3.69 (1 H, m, (t), H4'), 4.11 (1 H, m, (t), H2'), 4.65, 5.22, 5.35, 5.45 (4H, ex, 4 x OH), 5.58
(1 H, d, J = 9 Hz, H1 '), 7.51 - 7.69 (3H, m, 3,4,5H Bz), 8.06 (2H, d, J = 7 Hz, 2,6 H Bz), 8.70
(1 H, s, 8-H), 8.77 (1 H, s, 2-H), 11.21 (1 H, s, ex, NH); 13C-NMR (50 MHz, DMSO-d6): δ = 61.1
(CH26'), 69.9 (CH4'), 71.3 (CH2'), 77.3 (CH3'), 80.3 (CH5'), 83.2 (CH1 '), 125.7 (5-C), 128.7
(2,3,5,6CH Bz), 132.7 (4CH Bz), 133.6 (1-C Bz), 143.8 (2-CH), 150.5 (4-C), 152.0 (8 CH), 153.0 (6-C), 165.9 (C=O); MS (ESI; m/z (%)): 105 (40) [Bz]+, 240 (76), 262 (70) 402 (11)
[M+H]\ 424 (100) [M+Na]+, 446 (56) [M-H+2Na]+; Exact Mass: Cι8H2oN5O6: Calc: 402.1413;
Found: 402.1418.
N4-Benzoyl-1-(β-D-qlucopyranosyl)cvtosine: Yield: 1.04 g (90 %); Rf (ethyl acetate) 0.52, mp:
189-1919C (CH2CI2l lit: 191-192aC)18
INTRODUCTION OF MONOMETHOXYTRITYL IN THE 6' POSITION: GENERAL
PROCEDURE:
The mixture of nucleoside A orC (3.5 mmol), respectively and MMTCI (2.16 g, 7.0 mmol) in pyridine (20 mL) and triethylamine (5 mL) was stirred in an inert atmosphere at ambient temperature for 18 h. After removing the solvent in vacuo the resultant oil was coevaporated with toluene (4 x 2 mL). The resulted foam was purified by column chromatography. (silica, 15 x 3 cm, CH2CI2/MeOH = 9 : 1 ).
6'-0-Monomethoxytrityl-N6-benzoyl-9-(β-D-qlucopyranosyl)adenine: Yield: 1.6 g (70 %); R, (CH2CI2/MeOH = 9 : 1 ) 0.27, mp: 148 - 1529C; 1H-NMR (200 MHz, DMSO-d6): δ = 2.88 - 3.39 (6H, m, 2 x H6', H5', H3', H4', H2'), 3.70 (3H, s, CH3O), 5.17, 5.40, 5.53 (3H, ex, 4 x OH), 5.67 (1 H, d, J = 9 Hz, H1 '), 6.74 (2H, d , J = 8.4 Hz, AA'BB'), 7.24 - 7.59 (15H, m, CH MMT, Bz,), 8.06 (2H, d, J = 7 Hz, 2,6 H Bz), 8.72 (1 H, s, 8-H), 8.80 (1 H, s, 2-H), 1 1.25 (1 H, s, ex, NH); 13C-NMR (50 MHz, DMSO-d6): δ = 55.1 (CH3O), 63.9 (CH26'), 70.1 (CH4'), 71.2 (CH2'), 77.3 (CH3'), 78.2 (CH5'), 83.4 (CH1 '), 85.6 (C MMT), 96.9 (5-C), 113.2 (AA'BB', MMT), 125.8 (5-C), 126.9 - 130.3 (C Ar MMT + Bz), 132.6 (4CH Bz), 133.6 (1 C Bz), 135.4 (AA'BB' MMT), 143.6 (2-CH), 144.7 (2 x 1 C MMT), 150.3 (4-C), 151.9 (8-CH), 153.0 (6-C), 158.3 (4C AA'BB' MMT), 165.9 (C=O Bz); MS (ESI; m/z (%)): 105 (22), [Bz]+, 240 (37), 273 (100), [MMTJ+, 696 (30) [M + Na]+, 718 (8) [M - H + 2Na]+; Exact Mass: C38H36N5O7: Calc: 674.2614; Found: 674.2618.
6'-0-Monomethoxytrityl-N -benzoyl-1-(β-D-qlucopyranosyl)cvtosine: Yield: 2.27 g (83%); Rf (CH2CI2/MeOH = 9 : 1) 0.25, mp: 150 - 1549C; 1H-NMR (200 MHz, DMSO-d6): δ = 2.92 - 3.72 (6H, m, 2 x H6', H5', H3', H4', H2'), 3.68 (3H, s, CH3O), 5.10, 5.34, 5.43 (3H, ex, 4 x OH), 5.66 (1 H, d, J = 9 Hz, H1 '), 6.84 (2H, d , J = 8.4 Hz, AA'BB'), 7.24 - 7.63 (16H, m, CH MMT, Bz, 5-H), 8.01 (2H, d, J = 7 Hz, 2,6 H Bz), 8.21 (1 H, d, J = 7.6 Hz, 6-H), 11.28 (1 H, s, ex, NH); 13C-NMR (50 MHz, DMSO-d6): δ = 55.1 (CH3O), 64.1 (CH26'), 70.1 (CH4'), 71.8 (CH2'), 77.2 (CH3'), 78.5 (CH5"), 83.5 (CH1 '), 85.6 (C MMT), 96.9 (5-C), 1 13.3 (AA'BB', MMT), 126.9 - 130.3 (C Ar MMT + Bz), 133.0 (4CH Bz), 133.4 (1 C Bz), 135.4 (1 C AA'BB'), 144.5 (2 x 1C MMT), 146.3 (6-CH), 155.0 (2-C=O), 158.3 (4C AA'BB' MMT), 163.2 (C=O Bz); MS (ESI; m/z (%)): 105 (43), [Bz]+, 238 (40), 273 (100), [MMT]+, 672 (8) [M+Na]+; Exact Mass: C37H37N3O8: Calc: 651.2580; Found:. 651.2588.
OXIDATIVE RING OPENING OF A.C: GENERAL PROCEDURE:
To a solution of 6'-0-MMT nucleoside A,C respectively(1 mmol) in absolute dichloromethane (10 mL), Pb(OAc)4 (1.33 g, 3 mmol) is added under nitrogen at ambient temperature. The solution gets warm and turns yellow. After 2 h a colorless precipitate of Pb(OAc)2 is formed. Stirring is continued over night. After removing the solvent on a rotavapor the residue is purified by column chromatography (silica, 10 x 2 cm, CH2CI2/MeOH = 95 : 5). MS verified the structure of the resultant colorless foams because of the complicated equilibrium observed in the NMR.
5'-0-Monomethoxytrityl-N6-benzoyladenosine dialdehvde: Yield: 0.56 g (88 %); Rf (CH2CI2/MeOH = 95 : 5) 0.54, MS (LSIMS; Thgly; m/z (%)):273 (100) [MMT]+, 640 (2) [M + Na]\ 662 (1 ) [M - H + 2 Na]+. 5'-0-Monomethoxytrityl-N4-benzoylcvtidine dialdehvde: Yield: 0.57 g (92 %); Rf (CH2CI2/MeOH = 95 : 5) 0.49, MS (LSIMS; Thgly; m/z (%)):273 (100) [MMTj\ 664 (1 ) [M + Na]+, 686 (2.8) [M - H + 2 Na]+.
REDUCTIVE RING CLOSURE OF A.C: GENERAL PROCEDURE:
A,C-dialdehyde (1 mmol), respectively, was dissolved in absolute dioxane (8 mL) under a nitrogen atmosphere. Tri-n-butyltin hydride (0.43 g, 0.4 mL, 1.25 mmol) is added via a septum. The reaction mixture is heated to 90°C. Via the septum a solution of AIBN (0.02 g, 0.12 mmol) in dioxane (2 mL) is added. Foam is formed, after stirring for 30 min at 90°C the reaction mixture was checked with TLC (CH2CI2/MeOH = 95 : 5). If unreacted aldehyde is monitored on TLC, additional AIBN (0.01g, 0.06 mmol) and tri-n-butyltin hydride (0.1 1 g, 0.1 mL, 0.31 mmol) are added and stirring at 90°C is continued for another 60 min. After evaporating the solvent under reduced pressure the residue is purified by column chromatography (silica, 20 x 3 cm, CH2CI2 (100 mL) → CH2CI2/MeOH = 95 : 5).
5'-Monomethoxytrityl-N6-benzoyladenosine: Yield: 0.34g (53%); R, (CHaCVMeOH = 9 : 1 ) 0.49, mp: 122 -1259C (CH2CI2), (Lit: 120 - 1259C)19.
5'-Monomethoxytrityl-N4-benzoylcvtidine: Yield: 0.31 g (54 %); R, (CH2CI2/MeOH = 9 : 1 ) 0.38, mp: 140 -1469C (CH2CI2), (Lit: 140 -1469C)19.
PREPARATION OF ri '.2'.3'.4'.5'-13CJ-(2\3\5'-TRI-Q-ACETYL)URIDINE FROM M '.2'.3'.4'.5'- 3C;1-5'-0-MONOMETHOXYTRITYL-URIDINE:
A mixture of [1 ',2',3',4',5'-13C6]-5'-0-monomethoxytrityl-uridine (0.5 g, 1 mmol) in 80 % acetic acid (5 mL) was stirred at room temperature for 30 min. After addition of 50 mL water, the precipitate was filtered off, the solution was evaporated under reduced pressure. The resulted crude product was treated with acetic anhydride (2.5 mL) without further purification. After heating under reflux for 2 h, the reaction mixture was cooled to ambient temperature and neutralized with aqueous NaHCO3. The mixture was extracted with CH2CI2 (3 x 10 mL), the organic layer was dried over Na2SO and removed on the rotavapor. Further purification was achieved by column chromatography (silica, 10 x 3 cm, CH2Cl2/MeOH = 95 :5).
ri \2'.3'.4'.5'-13CfiH2'.3'.5'-Triacetyl)uridine: 0.28 g, (79 %); R, (CH2CI2/MeOH =9 : 1 ): 0.65; mp: 128 -130°C (MeOH); 1H-NMR (500 MHz, CDCI3): δ = 2.06, 2.10, 2.19 ( 3 x 3H, 3 x Ac), 4.31 (3H, m, J°H = 162 Hz, 2x H5\ H2"), 5.33 (2H, m, J°H = 162 Hz, H3', H4"), 5.76 (1 H, d, J = 8 Hz, H-5), 6.01 (1 H, °H = 160 Hz, ™ = 5 Hz, H1 '), 7.40 (1 H, J = 8 Hz, 6-H), 9.82 (1 H, s, br, ex, NH); 3C-NMR (50 MHz, CDCI3): δ = 20.2, 20.3, 20.5 (3 x CH3 Ac), 63.0 (d, J= 43 Hz, CH5'), 70.0 (t, J= 43 Hz, CH2'), 72.5 (t, J= 43 Hz, CH3'), 79.8 (t, J= 43 Hz, CH4'), 87.4 (d, J = 45 Hz, CH1'), 103.3 (s, 5-CH), 139.4 (s, 6-CH), 150.3 (s, 2-C), 163.1 (s, 4-C), 169.6, 169.7, 170.2 (3 x C=O Ac); MS (ESI; m/z (%)):139 (73), 259 (74), 376 (8) [M + H]+, 398 (100) [M + Na]+, 420 (36) [M - H + 2 Na]+; Exact Mass: C10C H18N2O9Na: Calc: 398.1078; Found:. 398. 1086.
TRANSGLYCOSYLATION OF U→G:
To the suspension of tri-O-acetyluridine (0.65 g, 1.77 mmol) and N2-isobutyrylguanine (2.35 g, 10.62 mmol) in dichloroethane (40 mL) BSA (12 mL, 50 mmol) was added. The mixture was heated under nitrogen to result in a clear, colorless solution. After addition of TMSOTf (2.4 mL, 13 mmol) under nitrogen the reaction mixture was heated under reflux for 10 h. After cooling to ambient temperature, brine (150 mL) was added. The precipitate was filtered off and washed with CH2CI2 (5 x 10 mL). After extracting the aqueous layer with CH2CI2 (30 mL) the combined organic layers were dried over Na2SO4. After evaporating the solvent the resulted oil was purified by column chromatography (silica, 24 x 3 cm, CH2CI2/MeOH = 95 : 5). (2'.3'.5'-Tri-Q-acetvn-N2-isobutyrylquanosine: Yield 0.73 g ( 86 %); R, (CH2CI2/MeOH = 95 : 5) 0.39; mp: 125 - 130 "C20.
References
[1.] Kainosho, M. (1997) Nature Struct. Biol. NMR Suppl., 858-861.
[2.] Milligan, J.F., Groebe, D.R., Witherell, G.W., Uhlenbeck, O.C. (1987) Nucleic Acids.
Res., 15, 8783-8799. Wyatt, J.R., Chastain, M., Puglisi, J.D. (1991 ) BioTechniques, 11, 764-769.
Nikonowicz, E.P., Sirr, A., Legault, P., Jucker, F.M., Baer, L.M., Pardi, A. (1992)
Nucleic Acids Res., 20, 4507-4513.
Batey, R.T., Inada, M., Kujawinski, E., Puglisi, J.D., Williamson, J.R. (1992) Nucleic
Acids Res., 20, 4515-4523. Michnicka, M.J., Harper, J.W., King, G.C. (1993) Biochemistry, 32, 395-400.
Nikonowicz, E.P., Pardi, A. (1993) J. Mol. Biol., 232, 1 141 -1156.
Hines, J.V., Landry, S.M., Varani, G., Tinoco Jr., I., (1994) J. Am. Chem. Soc, 116,
5823-5831. [3.] Parkin, D.W., Leung, H.B., Schramm, V.L. (1984; J. Biol. Chem., 259, 9411-9417. Parkin, D.W., Schramm, V.L. (1987) Biochemistry, 26, 913-920.
Gilles A.-M., Cristea, I., Palibroda, N., Hilden, I., Jensen, K.F., Sarfati, R.S., Namane,
A.,
Ughetto-Monfrin, J., Barzu, O. (1995) Anal. Biochem., 232, 197-203.
Tolbert, T.J., Williamson, J.R. (1997) J. Am. Chem. Soc, 119, 12100-12108. [4.] Zimmer, D.P., Crothers, D.M. (1995) Proc. Natl. Acad. Sci USA, 92, 3091-3095. [5.] G., Chazin, W.J. (1998) J. Am. Chem. Soc, 120, 607-608. [6.] Masse, J.E., Bortmann, P., Dieckmann, T., Feigon, J. (1998) Nucleic Acids Res., 26,
2618-
2624. [7.] Louis, J.M., Martin, R.G., Clore, G.M., Gronenborn, A.M. (1998) J. Biol. Chem., 273,
2374-
2378. [8.] Tate, S.-L, Ono, A., Kainosho, M. (1994) J. Am. Chem. Soc, 116, 5977-5978.
Tate, S.-i., Ono, A., Kainosho, M. (1995) J. Magn. Res. ser B, 106, 89-91. Szyperski, T., Ono, A., Fernandez, C, Iwai, H., Tate, S.-i., Wϋthrich, K., Kainosho, M.
(1997) J. Am. Chem. Soc, 9901 -9902. [9.] Kline, P.C., Serianni, A.S. (1990) J. Am. Chem. Soc, 112, 7373-7381.
Lancelot, G., Chanteloup, L, Beau, J.-M., Thuong, NT. (1993) J. Am. Chem. Soc, 115, 1599-1600.
Bomet, O., Lancelot, G., Chanteloup, L, Thuong, N ., Beau, J.-M. (1994) J. Biomol.
NMR,
4, 575-580. Ono, A., Tate, S.-i., Ishido, Y., Kainosho, M. 1994, J. Biomol. NMR, 4, 581-586.
Tolbert, T.J., Williamson, J.R. (1996) J. Am. Chem. Soc, 118, 7929-7940 [10.] Milecki, J., Zamaratski,E., Maltseva.T.V., Fόldesi.A., Adamiak.R.W., Chattopadhyaya, J.
(1999) Tetrahedron, 55, 6603-6622 [11.] Quant, S., Wechselberger, R.W., Wolter, M.A., Wόrner, K.-H., Schell, P., Engels,
J.W.,
Griesinger, C, Schwalbe, H. (1994) Tetrahedron Lett., 35, 6649-6652. [12.] Agrofoglio, LA., Jacquinet, J.-C, Lancelot, G. (1997) Tetrahedron Lett., 38, 1411 - 1412. [13.] Vorbruggen, H. and Bennua, B. (1981 ) Chem. Ber. ,114, 1234.
[14.] Howarth, O., Jones, A.S., Walker, R.T., Wyatt, P.G. (1984) J. Chem. Soc. Perkin Trans II,
261-265. [15.] Yamaoka, N., Asu, K., Matsuda, K. (1965) J. Org. Chem., 30, 149-152. [16.] Lerner, LM. and Kohn, P. (1965) J. Med. Chem., 7, 655-658.
[17.] Hubert, C.W. and Jansen, E.F. (1936) J. Am. Chem. Soc, 58, 60-62. [18.] Lichterthaler, F., Ueno.T., Voss, P. (1974) Bull. Chem. Soc. Jpn. 47, 2304-2307. [19.] Flockerzi, D., Silber, G., Charubala, R., Schlosser, W., Varma, R.S., Creegan, F., Pfleiderer, W., (1981 ) Liebigs Ann. Chem. 9, 1568 - 1585.
[20.] Robins, M.J., Zou, R., Guo, Z., Wnuk, S.F., (1996) J. Org. Chem., 61 , 9207-9212.

Claims

Claims
1 . Method for the chemical preparation of labeled nucleosides via an oxidative-ring- opening step and a reductive-ring-closure step starting from a labeled D-glucose nucleoside resulting in the corresponding D-ribose-nucleoside by removing the carbon atom 3 on the glucose.
2. Method according to claim 1 , wherein the reductive-ring-closure is obtained using a reducing agent.
3. The method of claim 1 or 2, wherein the reducing agent is sodium hypophosphite (NaH2PO2.H2O).
4. Method according to claim 1 or 2, wherein the reducing agent is Bu3SnH.
5. Method according to claim 1 or 2, wherein the reducing agent is Sml2.
6. Method according to claim 1 , wherein the reductive-ring-closure is obtained under radical-induced reductive conditions using a radical initiator and a reducing agent.
7. Method according to claim 6, wherein the radical initiator is AIBN.
8. The method of claim 6, wherein the radical initiator is AIBN and the reducing agent is a tin hydride.
9. The method of claim 6, wherein the radical initiator is AIBN and the reducing agent is tributyltin hydride (Bu3SnH or n-Bu3SnH).
10. Method according any of the claims 1 to 9, wherein the oxidative-ring-opening is performed using Pb(OAc)4.
1 1. Method according to any of the previous claims 1 -10, starting from partially or fully labeled D-glucose comprising the steps of:
- a protection of the sugar ring hydroxyl groups, - a sugar-base condensation, whereby the base is a purine or a pyrimidine,
- a deprotection of the sugar ring hydroxyl groups,
- an oxidative-ring-opening and removal of the carbon atom 3, and
- a reductive-ring-closure resulting in labeled D-ribose-nucleoside.
12. Method according to claims 1 1 , wherein the labeled glucose is from the group consisting of [13C6]-D-glucose or a partially labeled D-glucose.
13. Method according to claim 11 or 12, wherein the purine or pyrimidine of step 2 is fully or partially labeled.
14. Method according to claim 1 1 , 12 or 13, wherein step 3 is followed by a protection step of the primary OH-group.
15. Method according to claim 14, wherein the primary OH-group is protected as a trityl or silyl ether or by any other protecting group stable to the oxidative-ring-opening and reductive-ring-closure reactions.
16. Method according to claim 11 -15, wherein the protection step comprises a mono-d- C-6-alkyloxytritylation or a bis-Cι-C6-alkyloxytritylation of the primary hydroxyl function in the 6'-O-position of glucose.
17. Method according to claim 16, wherein the mono-d-C6-alkyloxy is mono-methyloxy or wherein the bis-Cι-C6-alkyloxy is di-methyloxy.
18. Method according to any of the claims 1 1 -17, wherein step 3 is followed by a protection step of the base moiety.
19. Method according to any of the previous claims 1-18, wherein if the nucleoside is uridine a transglycosylation step is performed with guanine resulting in guanosine.
20. Method according to any of the previous claims 1 -19, further comprising the functionalization of the obtained ribonucleosides into suitable building blocks for the chemical or enzymatic synthesis of labeled RNA.
21. Method according to any of the previous claims 1-20, further comprising the functionalization of the obtained ribonucleosides into protected ribonucleoside phosphoramidites, being preferably 2'-O-silyl protected ribonucleoside phosphoramidites.
22. Method according to any of the previous claims 1-21 , further comprising the deoxygenation of the obtained ribonucleosides into deoxyribonucleosides.
23. Method according to claim 22, further comprising the functionalization of the obtained deoxyribonucleosides into protected deoxyribonucleoside phosphoramidites.
24. Compound obtainable via the method according to any of the previous claims 1-18 having the formula selected from [13C,15N] labeled 6'-O-mono- or 6'-O-bis-d-C6- alkyloxytrityl-D-glucopyranosyl nucleosides, or [13C,15N] labeled tetra-O-acetyl-D- glucopyranosyl nucleosides or [13C,15N] labeled glucopyranosyl nucleosides.
25. Compound according to claim 24, wherein the mono-Cι-C6-alkyloxy is mono- methyloxy or wherein the bis-d-C6-alkyloxy is di-methyloxy.
26. Compound obtainable via the method according to any of the previous claims 1-23 having the formula of [ 3C,15N] labeled 5'-O-mono- or 5"-O-bis-Cι-C6-alkyloxythtyl- ribonucleosides.
27. Compound according to claim 26, wherein alkyloxy is methyloxy or ethyloxy.
28. Compound according to claim 26 or 27, wherein the ribonucleosides are naturally occurring nucleoside analogues.
29. Compound according to claim 26 or 27, wherein the ribonucleosides are chosen from the group comprising adenosine, guanosine, cytidine, uridine and 5-methyluridine, inosine, Λ^-methyladenosine, Λr^/V dimethyladenosine, /v^-methylguanosine, /V2,/^- dimethylguanosine, ΛΛ-methylcytidine and /V\Λ*-dimethylcytidine.
30. Compound obtainable via the method according to any of the previous claims 1-23, having the formula of [13C,15N] labeled 5'-O-mono- or 5'-O-bis-d-C6-alkyloxytrityl- deoxyribonucleosides.
31. Compound according to claim 30, wherein alkyloxy is methyloxy or ethyloxy.
32. Compound according to claim 30 or 31 , wherein the deoxyribonucleosides are chosen from deoxyadenosine, deoxyguanosine, deoxycytidine and thymidine.
33. Compound according to any of the previous claims 24-32, having the formula of: [1 ',2',3',4",5',6'-13C6]-[2',3',4',6'-tetra-0-acetyl-β-D-glucopyranosyl)uracil
[1,,2, I3, t4,,5,,6,-13Ce]- [2',3',4',6'-tetra-0-acetyl-β-D-glucopyranosyl)-[6-13C, 1 ,3-15N2]- uracil
[1 ',2,,3,,4',5',6'-13C6]-(β-D-glucopyranosyl)uracil
[1 , 12',3',4',5,,6'-13C6]-(β-D-glucopyranosyl)-(6-13C, 1 ,3-15N2)-uracil
[1 ')2',3',4',5',6'-13C6]-6'-0-monomethoxytrityl-(β- D-glucopyranosyl)uracil
[1 ',2'I3',4',5',6'-13C6]-6'-0-monomethoxytrityl-(β-D-glucopyranosyl)-[6-13C, 1 ,3-15N2]- uracil
[1',2',3',4',5',6'-13C6] (2',3*,4',6'-tetra-0-acetyl-β-D-glucopyranosyl)-N4-benzoylcytosine
[1 \2',3',4',5',6'-13C6] (2,,3',4',6'-tetra-0-acetyl-β-D-glucopyranosyl)-[6- 3C, 1 ,3,NH2-
15N3]-N4-benzoylcytosine
[1 ',2',3,,4',5',6'-13C6]-(β-D-glucopyranosyl)-cytosine [1 ,,2, f3,,4, l5,,6,-13CβJ-(β-D-glucopyranosyl)-[6-13C, 1 ,3,NH2-15N3]-cytosine
[1 ',2',3',4',5',6'-13C6]-(β-D-glucopyranosyl)-N4-benzoylcytosine
[1 ',2',3',4',5',6'-13C6]-(β-D-glucopyranosyl)-[6-13C, 1 ,3,NH2-15N3]-N4-benzoylcytosine
[1 ,,2',3')4',5',6'-13C6]-(6'-0-monomethoxytrityl-β-D-glucopyranosyl)-N -benzoylcytosine
[1 '^'.S'^'.S'.e'-^Cel^θ'-O-monomethoxytrityl-β-D-glucopyranosy -fe-^C, 1 ,3,NH2- 15N3]-N4-benzoylcytosine
[1 ',2',3',4',5'-13C5]-(2',3',5'-tri-0-acetyl)-uridine
[1 ,,2',3',4,,5',6'-13C6] (2',3',4,,6'-tetra-0-acetyl-β-D-glucopyranosyl)-N6-benzoyladenine
[1 \2',3',4',5',6'-13C6] (2',3',4',6'-tetra-0-acetyl-β-D-glucopyranosyl)-[8-13C, 9,NH2-15N2]- N6-benzoyladenine
[1 ',2',3',4',5,,6'-13C6]-(β-D-glucopyranosyl)-adenine
[1 ',2',3',4',5',6'-13C6]-(β-D-glucopyranosyl)-[8-13C, 9,NH2-15N2]-adenine
[1 '>2',3',4',5',6'-13C6]-(β-D-glucopyranosyl)-N6-benzoyladenine
[1 ',2',3',4',5',6'-13C6]-(β-D-glucopyranosyl)-[8-13C, 9,NH2-15N2]-N6-benzoyladenine
[1 ,,2',3',4',5',6'-13C6]-(6'-0-monomethoxytrityl-β-D-glucopyranosyl)-N6-benzoyladenine
[1 ,,2',3',4',5',6'-13C6]-(6'-0-monomethoxytrityl-β-D-glucopyranosyl)-[8-13C, 9,NH2-15N2]- N6-benzoyladenine.
34. Compound according to any of the claims 24-33 obtained via the method according to any of the previous claims 1-23.
35. Use of a compound according to any of the previous claims 24-34, in mass spectrometry and diagnostics.
36. Use of a compound according to any of the previous claims 24-34, for NMR applications.
37. Use of a compound obtainable via the method of claim 21 or claim 23 for oligonucleotide synthesis.
38. Compounds obtained by the method according to claim 1 -23.
PCT/EP2001/005366 2000-05-10 2001-05-10 Labeled nucleosides and method for their preparation WO2001085220A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU69003/01A AU6900301A (en) 2000-05-10 2001-05-10 Labeled nucleosides and method for their preparation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0011226A GB0011226D0 (en) 2000-05-10 2000-05-10 Conversion of glucopyranosyl nucleosides to ribofuranosyl: a short path for the synthesis of isotopically labeled nucleosides
GB0011226.8 2000-05-10
EP00870188A EP1186306A1 (en) 2000-09-05 2000-09-05 Labeled nucleosides and method for their preparation
EP00870188.0 2000-09-05

Publications (1)

Publication Number Publication Date
WO2001085220A1 true WO2001085220A1 (en) 2001-11-15

Family

ID=26074280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005366 WO2001085220A1 (en) 2000-05-10 2001-05-10 Labeled nucleosides and method for their preparation

Country Status (2)

Country Link
AU (1) AU6900301A (en)
WO (1) WO2001085220A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276592B2 (en) 2003-04-05 2007-10-02 Roche Diagnostics Operations, Inc. Nucleotide analogs with six-membered rings
RU2787350C1 (en) * 2021-12-30 2023-01-09 Общество С Ограниченной Ответственностью "Марлин Биотех" Method for producing morpholine oligomers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AGROFOGLIO, LUIGI A. ET AL: "A multigram, stereoselective synthesis of D-[ 13C5 ]ribose from D-[ 13C6 ]glucose and its conversion into [ 13C5 ]nucleosides", TETRAHEDRON LETT. (1997), 38(8), 1411-1412, XP002160124 *
MILECKI, JAN ET AL: "The first example of sequence-specific non-uniformly 13C5 labeled RNA: synthesis of the 29mer HIV-1 TAR RNA with 13C relaxation window", TETRAHEDRON (1999), 55(21), 6603-6622, XP002160122 *
ONO, AKIRA ET AL: "Preparation and heteronuclear 2D NMR spectroscopy of a DNA dodecamer containing a thymidine residue with a uniformly 13C-labeled deoxyribose ring", J. BIOMOL. NMR (1994), 4(4), 581-6, XP000982201 *
ONO, AKIRA MEI ET AL: "Systematic synthesis of specifically 13C/2H-labeled nucleosides from [ul-13C6]-D-glucose", TETRAHEDRON LETT. (1998), 39(18), 2793-2796, XP002160123 *
QUANT, S. ET AL: "Chemical synthesis of 13C-labeled monomers for the solid-phase and template controlled enzymic synthesis of DNA and RNA oligomers", TETRAHEDRON LETT. (1994), 35(36), 6649-52, XP002160278 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276592B2 (en) 2003-04-05 2007-10-02 Roche Diagnostics Operations, Inc. Nucleotide analogs with six-membered rings
RU2787350C1 (en) * 2021-12-30 2023-01-09 Общество С Ограниченной Ответственностью "Марлин Биотех" Method for producing morpholine oligomers

Also Published As

Publication number Publication date
AU6900301A (en) 2001-11-20

Similar Documents

Publication Publication Date Title
Mansuri et al. Preparation of 1-(2, 3-dideoxy-. beta.-D-glycero-pent-2-enofuranosyl) thymine (d4T) and 2', 3'-dideoxyadenosine (ddA): general methods for the synthesis of 2', 3'-olefinic and 2', 3'-dideoxy nucleoside analogs active against HIV
FI108643B (en) Stereoselective glycosylation procedure for the preparation of a nucleoside enriched in beta
EP1015469B2 (en) Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
US5506347A (en) Lyxofuranosyl analogues of adenosine
US8153365B2 (en) Oligonucleotide analogues
Secrist III et al. Synthesis and anti-HIV activity of 4'-thio-2', 3'-dideoxynucleosides
JP2004522695A (en) Method for synthesizing nucleoside, nucleoside derivative and non-nucleoside derivative
CA2206878A1 (en) L-nucleoside dimer compounds and therapeutic uses
HU199499B (en) Process for producing 2&#39;,3&#39;-dideoxy-2&#39;-fluoronucleosides and pharmaceutical compositions comprising such active ingredient
US3928319A (en) 4 -Fluoro nucleosides, novel intermediates and methods of preparing same
WO2006070985A1 (en) METHOD FOR THE PREPARATION OF 2&amp;num;-DEOXY-2&amp;num;,2&amp;num;-DIFLUOROCYTIDINE
Rahim et al. Synthesis and biological properties of 2′-deoxy-5-vinyluridine and 2′-deoxy-5-vinylcytidine
JPH06228186A (en) 2&#39;-deoxy-@(3754/24)2&#39;s)-alkylpyrimidine nucleoside derivative
WO2019053476A1 (en) Floxuridine synthesis
Augustyns et al. Influence of the Incorporation of 1‐(2, 3‐Dideoxy‐β‐D‐Erythro‐Hexopyranosyl)‐Thymine on the Enzymatic Stability and Base‐Pairing Properties of Oligodeoxynucleotides
JPH0853490A (en) 2&#39;-deoxy-2&#39;,2&#39;-dihalogeno-4&#39;-thionucleoside
WO1996001834A1 (en) 2&#39;-deoxy-2&#39;-(substituted or unsubstituted methylidene)-4&#39;-thionucleoside
JP4994557B2 (en) Uridine derivatives as antibiotics
Mikhailopulo et al. Oxidation-reduction sequence for the synthesis of peracylated fluorodeoxy pentofuranosides
Nomura et al. Nucleosides and nucleotides. Part 212: Practical large-scale synthesis of 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) cytosine (ECyd), a potent antitumor nucleoside. Isobutyryloxy group as an efficient anomeric leaving group in the Vorbrüggen glycosylation reaction
WO2001085220A1 (en) Labeled nucleosides and method for their preparation
BrianáLamont Enantiospecific synthesis of 3′-hetero-dideoxy nucleoside analogues as potential anti-HIV agents
EP1186306A1 (en) Labeled nucleosides and method for their preparation
JPH09328497A (en) 4&#39;-fluoromethylnucleoside
EP0828749B1 (en) Methods for the synthesis of organophosphorus derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP